Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Bone Miner Res. 2013 Feb;28(2):283–290. doi: 10.1002/jbmr.1747

Fig. 5.

Fig. 5

An MMP3 inhibitor blocks E2-mediated FasL cleavage in primary calvarial osteoblasts. Primary murine calvarial osteoblasts were differentiated for 10 days, followed by treatment with vehicle control (EtOH), 10 nM E2 and/or 1 µM MMP3 inhibitor for 24 hours. The conditioned media was removed and subjected to ELISA for FasL. * = p-value <0.01 E2 vs. vehicle, MMP3I and E2+MMP3I. (MMP3I=specific MMP3 inhibitor)